NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Net Cash Flow of -$17.6 million for Q4 2025, down 59.33% year-on-year from -$43.3 million in Q4 2024, and down 128.15% on a QoQ basis from $62.6 million in Q3 2025.

NovaBridge Biosciences (NBP) Net Cash Flow (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Net Cash Flow for 4 consecutive years, with -$17.6 million the latest figure, recorded in Q4 2025.

  • Quarterly Net Cash Flow fell 59.33% year-over-year to -$17.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45.0 million (up 153.35% YoY) and the FY2025 annual result came in at $142.1 million, up 175.17% from the prior year.
  • Net Cash Flow eased to -$17.6 million in Q4 2025 per NBP's latest filing, from $62.6 million in the prior quarter.
  • Over the last five years, Net Cash Flow for NBP reached as high as $62.6 million in Q3 2025 and fell as low as -$73.2 million in Q3 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 10.56 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 224.46 Mn
4 NuCana 279.75 Bn 279.75 Bn - -1.34 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 457.40 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -152.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 57.19 Mn
10 NovaBridge Biosciences 389.86 Mn 389.86 Mn - -17.62 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -17.62 Mn
Dec 31, 2025 -17.62 Mn
Sep 30, 2025 62.59 Mn
Sep 30, 2025 62.59 Mn
Dec 31, 2024 -11.06 Mn
Dec 31, 2024 -11.06 Mn
Sep 30, 2024 -73.23 Mn
Sep 30, 2024 -73.23 Mn
Dec 31, 2020 289.03 Mn
Dec 31, 2020 289.03 Mn
Sep 30, 2020 239.14 Mn
Sep 30, 2020 239.14 Mn
Dec 31, 2019 -3.60 Mn
Dec 31, 2019 -3.60 Mn